Additive effect of Tadalafil and Simvastatin on monocrotaline-induced pulmonary hypertension rats

Scandinavian Cardiovascular Journal

Volumn 46, Issue 6, 2012, Pages 374-380

  Zhang, Wei Hua ^a   Liu, Chun Ping ^a   Zhang, Yun Jian ^b   Ji, Ying Qun ^c   Lu, Wei Xuan ^d   Zeng, Qiang ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b Jishuitan Orthopaedic College of Tsinghua University   (China)

^c DALIAN MEDICAL UNIVERSITY   (China)

^d PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

3 hydroxy 3 methylglutaryl (HMG) CoA reductase inhibitor; Interleukin 6; Phosphodiesterase 5 inhibitor; Pulmonary hypertension; Simvastatin; Tadalafil

Indexed keywords

INTERLEUKIN 6; MONOCROTALINE; PLACEBO; SIMVASTATIN; TADALAFIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIOLE; ARTICLE; BODY WEIGHT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; HEART RATE; HEART RIGHT VENTRICLE HYPERTROPHY; HISTOPATHOLOGY; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; MALE; MEAN ARTERIAL PRESSURE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT; VASCULITIS;

ANIMALS; ANTIHYPERTENSIVE AGENTS; ARTERIAL PRESSURE; ARTERIOLES; CARBOLINES; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; HEART RATE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; INFLAMMATION MEDIATORS; INTERLEUKIN-6; MALE; MONOCROTALINE; PHOSPHODIESTERASE 5 INHIBITORS; PULMONARY ARTERY; RATS; RATS, SPRAGUE-DAWLEY; SIMVASTATIN; TIME FACTORS; VASODILATOR AGENTS;

EID: 84870048713     PISSN: 14017431     EISSN: 16512006     Source Type: Journal    
DOI: 10.3109/14017431.2012.729272     Document Type: Article

References (26)

1. Rubin LJ. Primary pulmonary hypertension. N Engl J Med. 1997; 336: 111-117.
2. Runo JR, Loyd JE. Primary pulmonary hypertension. Lancet. 2003; 361: 1533-1544.
3. European Society of Cardiology and the European Respiratory Society. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2009; 30: 2493-510.
4. Provencher S, Sitbon O, Humbert M, Cabrol S, Jais X, Simonneau G. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J. 2006; 27: 589-595.
5. Falk J A, Philip K J, Schwarz E R. The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension. Vasc Health Risk Manag. 2010; 6: 273-280.
6. Sawamura F, Kato M, Fujita K, Nakazawa T, Beardsworth A. Tadalafil, along-acting inhibitor of PDE5, improves pulmonary hemodynamics and survival rate of monocrotalineinduced pulmonary artery hypertension in rats. J Pharmacol Sci. 2009; 111: 235-243.
7. Gali è N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z; Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009; 119: 2894-2903.
8. AS, Poston R, Ferro A. The lipid and non-lipid effects of statins. Pharmacol Ther. 2003; 99: 95-112.
9. Nishimura T, Faul J L, Berry G J, Vaszar L T, Qiu D, Pearl R G, Kao PN. Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. Am J Respir Crit Care Med. 2002; 166: 1403-1408.
10. Taraseviciene-Stewart L, Scerbavicius R, Choe KH, Cool C, Wood K, Tuder RM, et al. Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2006; 291: L668-676.
11. Wilkins MR, Ali O, Bradlow W, Wharton J, Taegtmeyer A, Rhodes CJ et al. Simvastatin as a treatment for pulmonary hypertension trial. AM J Respir Crit Care. 2010; 181: 1106-1113.
12. Howell K, Preston RJ, McLoughlin P. Chronic hypoxia causes angiogenesis in addition to remodelling in the adult rat pulmonary circulation. J Physiol. 2003; 547: 133-145.
13. Dumitrascu R, Koebrich S, Dony E, Weissmann N, Savai R, Pullamsetti SS, et al. Characterization of a murine model of monocrotaline pyrrole-induced acute lung injury. BMC Pulm Med. 2008; 8: 25.
14. Laufs U, Fata VL, Liao JK. Inhibition of 3-hydroxy-3- methylglutaryl (HMG)-CoA reductase blocks hypoxiamediated down-regulation of endothelial nitric oxide synthase. J Biol Chem. 1997; 272: 31725-31729.
15. Yen CH, Leu S, Lin YC, Kao YH, Chang LT, Chua S, et al. Sildenafil limits monocrotaline-induced pulmonary hypertension in rats through suppression of pulmonary vascular remodeling. Cardiovasc Pharmacol. 2010; 55: 574-584.
16. Sebkhi A, Strange J W, Phillips S C, Wharton J, Wilkins M R. Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension. Circulation. 2003; 107: 3230-3235.
17. Li B, Yang L, Shen J, Wang C, Jiang Z. The antiproliferative effect of sildenafil on pulmonary artery smooth muscle cells is mediated via upregulation of mitogen-activated protein kinase phosphatase-1 and degradation of extracellular signal-regulated kinase 1/2 phosphorylation. Anesth Analg. 2007; 105: 1034-1041.
18. Hsu HH, Ko WJ, Hsu JY, Chen JS, Lee Y C, Lai IR, et al. Simvastatin ameliorates established pulmonary hypertension through a heme oxygease-1 dependent pathway in rats. Respir Res. 2009; 10: 32.
19. Wright JL, Zhou S, Preobrazhenska O, Marshall C, Sin DD, Laher I, et al. Statin reverses smoke-induced pulmonary hypertension and prevents emphysema but not airway remodeling. Am J Respir Crit Care Med. 2011; 183: 50-58.
20. Tuder RM, Groves B, Badesch D B, Voelkel N F. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol. 1994; 144: 275-285.
21. Chaouat A, Savale L, Chouaid C, Tu L, Sztrymf B, Canuet M, et al. Role for interleukin-6 in COPD-related pulmonary hypertension. Chest. 2009; 136: 678-687.
22. Humbert M, Monti G, Brenot F, Sitbon O, Portier A, Grangeot-Keros L, et al. Increased interleukin-1 and interleukin- 6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med. 1995; 151: 1628-1631.
23. Yoshio T, Masuyama J I, Kohda N, Hirata D, Sato H, Iwamoto M, et al. Association of interleukin 6 release from endothelial cells and pulmonary hypertension in SLE. J Rheumatol. 1997; 24: 489-495.
24. Golembeski SM, West J, Tada Y, Fagan KA. Interleukin-6 causes mild pulmonary hypertension and augments hypoxiainduced pulmonary hypertension in mice. Chest. 2005; 128: 572S - 573S.
25. Steiner M K, Syrkina O L, Kolliputi N, Mark E J, Hales C A, Waxman AB. Interleukin-6 over expression induces pulmonary hypertension. Circ Res. 2009; 104: 236-244.
26. Savale L, Tu L, Rideau D, Izziki M, Maitre B, Adnot S, Eddahibi S. Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice. Respir Res. 2009; 10: 6.